2,6-Methano-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-, 1,1-dimethylethyl ester | 1824385-40-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 6,7-苯并吗啡烷
• 英文名称: 2,6-Methano-3-benzazocine-3(2H)-carboxylic acid, 1,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-, 1,1-dimethylethyl ester
• 英文别名: tert-butyl 4-hydroxy-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-triene-10-carboxylate
• CAS: 1824385-40-1
• 化学式: C₁₉H₂₇NO₃
• 分子量: 317.4
• InChiKey: YGTICUOLWDVEOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Morphan and Morphinan Analogues, and Methods of Use
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20150045384A1

  公开（公告）日：2015-02-12

  The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.

  本申请涉及到morphan和morphinan的类似物，其组成物以及治疗疾病或病情的方法，包括向需要的受试者投与足够量的化合物或组成物。
• Methods for Treating Depressive Symptoms
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20150072971A1

  公开（公告）日：2015-03-12

  The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.

  本申请涉及治疗抑郁症状的方法，包括向需要治疗的对象施用有效量的μ阿片受体激动剂或其药学上可接受的盐。此类激动剂的非限定性示例包括公式I、II、III和IV的化合物，以及表A中的化合物。
• MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE
  申请人：ALKERMES PHARMA IRELAND LIMITED

  公开号：US20150376197A1

  公开（公告）日：2015-12-31

  The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.

  本申请涉及morphan和morphinan的类似物，其组成物和治疗疾病或病况的方法，包括向需要的受试者施用化合物或组成物的有效剂量。
• Methods for treating depressive symptoms
  申请人：Alkermes Pharma Ireland Limited

  公开号：US10231963B2

  公开（公告）日：2019-03-19

  The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.

  本申请涉及治疗抑郁症状的方法，包括向有需要的受试者施用有效量的μ阿片受体激动剂或其药学上可接受的盐。此类激动剂的非限制性实例包括式I、II、III和IV化合物以及表A化合物。
• Morphan and morphinan analogues, and methods of use
  申请人：Alkermes Pharma Ireland Limited

  公开号：US10287250B2

  公开（公告）日：2019-05-14

  The present application relates to analogs of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.

  本申请涉及吗啡烷和吗啡烷的类似物、其组合物以及治疗疾病或病症的方法，其中包括向有需要的受试者施用有效量的化合物或组合物。